What did we learn from Big Pharma’s Q2 results?

Big Pharma maintained robust financial performance throughout the second quarter, with nine of the top 25 drug makers achieving double-digit revenue growth despite looming patent cliffs and shifting regulatory environments. Pharmaceutical companies are moving beyond general AI hype, integrating specific productivity tools like Copilot and Claude while applying proprietary models to accelerate drug discovery and optimize late-stage clinical trial design. The obesity market remains a primary growth driver, as Eli Lilly and Novo Nordisk escalate competition with new oral GLP-1 formulations. Meanwhile, organizational shifts define the current landscape, exemplified by Sanofi’s aggressive R&D pipeline restructuring under new leadership and Sarepta’s efforts to navigate safety-related commercial hurdles for its Duchenne muscular dystrophy gene therapy. These developments reflect a broader industry focus on balancing immediate financial gains with the long-term necessity of refining pipeline efficiency and maintaining competitive market share.